Lactoferrin vs TA1
A side-by-side research comparison of Lactoferrin and TA1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Lactoferrin | TA1 |
|---|---|---|
| Full name | Lactoferrin (Iron-Binding Glycoprotein) | Thymosin Alpha-1 (TA1 - Clinical Form) |
| Category | Immune Support | Immune Support |
| Status | Dietary supplement (GRAS) | Approved internationally (not FDA-approved) |
| Mechanism | Sequesters iron from pathogens (bacteriostatic), directly disrupts bacterial membranes, activates NK cells and macrophages, and modulates inflammatory cytokines. | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. |
| Molecular weight | 80000 Da | 3108.3 Da |
| Half-life | ~4-8 hours (oral absorption of fragments) | ~2-3 hours |
| Bioavailability | ~15-25% (oral, as bioactive fragments) | ~85% subcutaneous |
| Typical dose | 200-600 mg | 1.6 mg |
| Frequency | 1-2x daily | 2x per week |
| Route | Oral capsule or powder | Subcutaneous injection |
Lactoferrin reported benefits
- Broad antimicrobial activity
- Iron homeostasis regulation
- Gut immune support
- Anti-biofilm properties
- Prebiotic effects
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Related comparisons
Research and educational reference only. Not medical advice.